Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in Leishmania.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31819054.
- Also identified by DOI 10.1038/s41467-019-13344-6 and PMC identifier 6901541.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Current genome-wide screens allow system-wide study of drug resistance but detecting small nucleotide variants (SNVs) is challenging. Here, we use chemical mutagenesis, drug selection and next generation sequencing to characterize miltefosine and paromomycin resistant clones of the parasite Leishmania. We highlight several genes involved in drug resistance by sequencing the genomes of 41 resistant clones and by concentrating on recurrent SNVs. We associate genes linked to lipid metabolism or to ribosome/translation functions with miltefosine or paromomycin resistance, respectively. We prove by allelic replacement and CRISPR-Cas9 gene-editing that the essential protein kinase CDPK1 is crucial for paromomycin resistance. We have linked CDPK1 in translation by functional interactome analysis, and provide evidence that CDPK1 contributes to antimonial resistance in the parasite. This screen is powerful in exploring networks of drug resistance in an organism with diploid to mosaic aneuploid genome, hence widening the scope of its applicability.
Medical subject headings
- Drug Resistance
- High-Throughput Nucleotide Sequencing
- Leishmania
- Mutagenesis
- Mutation
- Paromomycin
- Phosphorylcholine